References
- Gummin DD, Mowry JB, Beuhler MC, et al. 2020 Annual report of the American association of poison control centers’ national poison data system (NPDS): 38th annual report. Clin Toxicol. 2021;59(12):1282–1501.
- Klein-Schwartz W, Stassinos GL, Isbister GK. Treatment of sulfonylurea and insulin overdose. Br J Clin Pharmacol. 2016;81(3):496–504.
- McCall AL. Clinical review of glimepiride. Expert Opin Pharmacother. 2001;2(4):699–713.
- Drugbank online. Glimepiride. 2022. [Accessed 15 August 2022]. Available from: https://go.drugbank.com/drugs/DB00222
- Shukla UA, Chi EM, Lehr KH. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Ann Pharmacother. 2004;38(1):30–35.
- Niemi M, Cascorbi I, Timm R, et al. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther. 2002;72(3):326–332.